Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer.
Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body.
EVT801 is an inhibitor of VEGFR3, a cellular receptor for VEGF. The Company’s drug candidates are designed to treat disease, such as brain cancer, renal cancer, and liver cancer..
Price and Volume | |
---|---|
Volume | |
Ten Day Average Volume | 708.3K |
Three Month Average Volume | 271.0M |
High Low | |
Fifty-Two Week High | 1.58 USD |
Fifty-Two Week Low | 0.1866 USD |
Fifty-Two Week High Date | 11 Jul 2024 |
Fifty-Two Week Low Date | 06 Mar 2024 |
Price and Volume | |
Current Price | 0.4233 USD |
Beta | 2 |
Relative Price Change | |
Four Week Relative Price Change | 24.43% |
Thirteen Week Relative Price Change | 52.12% |
Twenty-Six Week Relative Price Change | 49.86% |
Fifty-Two Week Relative Price Change | -62.88% |
Year-to-Date Relative Price Change | -18.67% |
Price Change | |
One Day Price Change | 8.12% |
Thirteen Week Price Change | 62.81% |
Twenty-Six Week Price Change | 64.77% |
Five Day Price Change | 17.58% |
Fifty-Two Week Price Change | -53.49% |
Year-to-Date Price Change | -3.69% |
Month-to-Date Price Change | 13.49% |
Per Share Data | |
---|---|
Book Value | |
Book Value Per Share (Last Fiscal Year) | 0.35745 USD |
Book Value Per Share (Most Recent Quarter) | 0.35745 USD |
Tangible Book Value Per Share (Last Fiscal Year) | -0.15481 USD |
Tangible Book Value Per Share (Most Recent Quarter) | -0.15481 USD |
EBITD | |
EBITD Per Share (Trailing Twelve Months) | -0.81685 USD |
Revenue | |
Revenue Per Share (Last Fiscal Year) | 0.00083 USD |
Revenue Per Share (Trailing Twelve Months) | 0.00083 USD |
Dividend | |
Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
Dividend Per Share (Trailing Twelve Months) | 0 USD |
Dividend Per Share (5 Year) | -99999.99 USD |
Earnings Per Share | |
Excluding Extraordinary Items (Last Fiscal Year) | -0.75114 USD |
Excluding Extraordinary Items (Trailing Twelve Months) | -0.83961 USD |
Normalized (Last Fiscal Year) | -0.83197 USD |
Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.75114 USD |
Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.83961 USD |
Including Extraordinary Items (Last Fiscal Year) | -0.75114 USD |
Including Extraordinary Items (Trailing Twelve Months) | -0.83961 USD |
Cash | |
Cash Per Share (Last Fiscal Year) | 0.15547 USD |
Cash Per Share (Most Recent Quarter) | 0.15547 USD |
Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
Free Cash Flow Per Share (Trailing Twelve Months) | -0.55629 USD |
Margins | |
---|---|
Cash Flow Revenue | |
Cash Flow Revenue (5 Year) | -406 |
Cash Flow Revenue (Trailing Twelve Months) | -67,182 |
Pretax Margin | |
Pretax Margin (Trailing Twelve Months) | -91,916.09% |
Pretax Margin (Last Fiscal Year) | -91,916.09% |
Pretax Margin (5 Year) | -508.32% |
Gross Margin | |
Gross Margin (Last Fiscal Year) | -99,999.99% |
Gross Margin (Trailing Twelve Months) | -99,999.99% |
Gross Margin (5 Year) | -99,999.99% |
Operating Margin | |
Operating Margin (Last Fiscal Year) | -91,918.57% |
Operating Margin (Trailing Twelve Months) | -91,918.53% |
Operating Margin (5 Year) | -495.72% |
Net Profit Margin | |
Net Profit Margin (Last Fiscal Year) | -90,714.45% |
Net Profit Margin (Trailing Twelve Months) | -90,714.45% |
Net Profit Margin (5 Year) | -497.17% |
Growth | |
---|---|
Book Value | |
Book Value Per Share (5 Year) | -33.21% |
Tangible Book Value (5 Year) | -99,999.99% |
Free Operating Cash Flow | |
Free Operating Cash Flow (5 Year) | -99,999.99% |
Revenue | |
Revenue Change MRQ vs 1 Year Ago | 20,281.82% |
Revenue Growth (3 Year) | -28.31% |
Revenue Change (Trailing Twelve Months) | 974.29% |
Revenue Per Share Growth | -44.67% |
Revenue Growth (5 Year) | -30.05% |
Capital Spending Debt | |
Capital Spending (5 Year) | -99,999.99% |
Total Debt (5 Year) | -99,999.99% |
Dividends | |
Dividend Growth (3 Year) | -99,999.99% |
Earnings Per Share | |
EPS Change MRQ vs 1 Year Ago | 65.28% |
EPS Change (Trailing Twelve Months) | 34.28% |
EPS Growth (3 Year) | -99,999.99% |
EPS Growth (5 Year) | -99,999.99% |
EBITDA | |
EBITDA (5 Year) | -99,999.99% |
EBITDA (5 Year Interim) | -99,999.99% |
Net Profit Margin | |
Net Profit Margin Growth (5 Year) | -99,999.99% |
Valuation | |
---|---|
Total Price to Book | |
Price to Tangible Book (Last Fiscal Year) | -100,000 |
Price to Tangible Book (Most Recent Quarter) | -100,000 |
Price to Free Cash Flow | |
Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
Net Debt | |
Net Debt (Most Recent Quarter) | -2,329,990 |
Net Debt (Last Fiscal Year) | -2,329,990 |
Price to Sales | |
Price to Sales (Last Fiscal Year) | 826 |
Price to Sales (Trailing Twelve Months) | 826 |
Price to Earnings | |
PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
PE Normalized (Last Fiscal Year) | -100,000 |
PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
Dividends | |
Dividend Yield (5 Year) | -99,999.99% |
Dividend Yield | -99,999.99% |
Current Dividend Yield | 0.00% |
Price to Book | |
Price to Book (Last Fiscal Year) | 1 |
Price to Book (Most Recent Quarter) | 1 |
Financial Strength | |
---|---|
Debt to Equity | |
Long Term Debt to Equity (Last Fiscal Year) | 0 |
Long Term Debt to Equity (Most Recent Quarter) | 0 |
Payout Ratio | |
Payout Ratio (Last Fiscal Year) | -99,999.99% |
Payout Ratio (Trailing Twelve Months) | -99,999.99% |
Quick Ratio | |
Quick Ratio (Last Fiscal Year) | -100,000 |
Quick Ratio (Most Recent Quarter) | -100,000 |
Enterprise Value | |
Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
Current Ratio | |
Current Ratio (Last Fiscal Year) | 1 |
Current Ratio (Most Recent Quarter) | 1 |
Free Cash Flow | |
Free Cash Flow (Last Fiscal Year) | -10,251,590 |
Free Cash Flow (Trailing Twelve Months) | -10,251,590 |
Net Interest Coverage | |
Net Interest Coverage (Last Fiscal Year) | -100,000 |
Net Interest Coverage (Trailing Twelve Months) | -100,000 |
Total Debt to Equity | |
Total Debt to Equity (Last Fiscal Year) | 15 |
Total Debt to Equity (Most Recent Quarter) | 15 |
Management Effectiveness | |
---|---|
Return on Assets | |
Return on Assets (Last Fiscal Year) | -63.98% |
Return on Assets (Trailing Twelve Months) | -63.98% |
Return on Assets (5 Year) | -46.35% |
Return on Equity | |
Return on Equity (Last Fiscal Year) | -134.97% |
Return on Equity (Trailing Twelve Months) | -134.97% |
Return on Equity (5 Year) | -76.57% |
Return on Investment | |
Return on Investment (Last Fiscal Year) | -82.39% |
Return on Investment (Trailing Twelve Months) | -82.39% |
Return on Investment (5 Year) | -54.75% |